Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Encoded Therapeutics launches with $104 million
by Ryan Cross
June 29, 2019
| A version of this story appeared in
Volume 97, Issue 26
The gene-therapy start-up Encoded Therapeutics has emerged from stealth mode after raising $104 million in series C financing. The company’s lead program is for a type of epilepsy called Dravet syndrome, caused by a deficiency in a sodium channel. The sodium channel gene is too large to be delivered via viral gene therapy, so Encoded scientists devised a creative fix: they made a synthetic transcription factor that boosts expression of the gene, which itself is delivered with gene therapy. They’ve successfully tested the concept in mice and monkeys.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter